BR112023023650A2 - Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras - Google Patents

Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras

Info

Publication number
BR112023023650A2
BR112023023650A2 BR112023023650A BR112023023650A BR112023023650A2 BR 112023023650 A2 BR112023023650 A2 BR 112023023650A2 BR 112023023650 A BR112023023650 A BR 112023023650A BR 112023023650 A BR112023023650 A BR 112023023650A BR 112023023650 A2 BR112023023650 A2 BR 112023023650A2
Authority
BR
Brazil
Prior art keywords
egfr
effector cell
compositions
tumor
cell antigens
Prior art date
Application number
BR112023023650A
Other languages
English (en)
Portuguese (pt)
Inventor
David Campbell
R Diraimondo Thomas
Original Assignee
Janux Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janux Therapeutics Inc filed Critical Janux Therapeutics Inc
Publication of BR112023023650A2 publication Critical patent/BR112023023650A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112023023650A 2021-05-12 2022-05-04 Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras BR112023023650A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187690P 2021-05-12 2021-05-12
US202263327317P 2022-04-04 2022-04-04
PCT/US2022/027688 WO2022240637A2 (en) 2021-05-12 2022-05-04 Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens

Publications (1)

Publication Number Publication Date
BR112023023650A2 true BR112023023650A2 (pt) 2024-01-30

Family

ID=84029363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023650A BR112023023650A2 (pt) 2021-05-12 2022-05-04 Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras

Country Status (12)

Country Link
US (3) US12161724B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337697A4 (cg-RX-API-DMAC7.html)
JP (1) JP7888613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240035392A (cg-RX-API-DMAC7.html)
CN (1) CN117642156A (cg-RX-API-DMAC7.html)
AR (1) AR125758A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022272906A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023650A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218661A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013382A (cg-RX-API-DMAC7.html)
TW (1) TW202311289A (cg-RX-API-DMAC7.html)
WO (1) WO2022240637A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116981682A (zh) * 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
WO2025195305A1 (en) * 2024-03-16 2025-09-25 Vibrant Pharma Limited Multispecific antigen binding proteins and uses thereof
WO2025201240A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2025201560A1 (en) * 2024-03-29 2025-10-02 Vibrant Pharma Limited Multispecific antigen-binding proteins and uses thereof
WO2026067689A1 (zh) * 2024-09-28 2026-04-02 浙江道尔生物科技有限公司 肿瘤特异性激活的蛋白药物及其应用
US20260226165A1 (en) * 2024-12-17 2026-08-06 Merck Sharp & Dohme Llc Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
BR112013002167A2 (pt) * 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103382223B (zh) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
IN2014MN02293A (cg-RX-API-DMAC7.html) 2012-04-20 2015-08-07 Emergent Product Dev Seattle
PE20150605A1 (es) * 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
JP6092649B2 (ja) 2013-02-15 2017-03-08 キヤノン株式会社 演算装置、アレイ型演算装置およびその制御方法、情報処理システム
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CN105820248A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
JP2018524373A (ja) 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
US20230220105A1 (en) 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
US20230312729A1 (en) 2019-06-26 2023-10-05 Amunix Pharmaceuticals, Inc. Egfr antigen binding fragments and compositions comprising same
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
KR20210043475A (ko) 2019-10-10 2021-04-21 주식회사 와이바이오로직스 다중 특이적 융합 단백질 및 이의 용도
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
WO2022094299A2 (en) 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
CN116981682A (zh) 2020-12-08 2023-10-31 佳努克斯治疗公司 用于抗-cd3结合结构域的肽组合物和方法
CN117616137A (zh) 2021-05-11 2024-02-27 佳努克斯治疗公司 靶向egfr和cd3的抗体及其用途
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
EP4615514A2 (en) 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2024100451A2 (en) 2022-11-11 2024-05-16 Janux Therapeutics, Inc. Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens

Also Published As

Publication number Publication date
EP4337697A4 (en) 2025-05-14
US12161724B2 (en) 2024-12-10
KR20240035392A (ko) 2024-03-15
US20240252669A1 (en) 2024-08-01
US12433953B2 (en) 2025-10-07
TW202311289A (zh) 2023-03-16
CA3218661A1 (en) 2022-11-17
AU2022272906A1 (en) 2023-11-30
JP2024518539A (ja) 2024-05-01
EP4337697A2 (en) 2024-03-20
MX2023013382A (es) 2024-01-30
US20250177552A1 (en) 2025-06-05
WO2022240637A3 (en) 2022-12-15
JP7888613B2 (ja) 2026-07-13
US20260014267A1 (en) 2026-01-15
AU2022272906A9 (en) 2023-12-07
CN117642156A (zh) 2024-03-01
WO2022240637A2 (en) 2022-11-17
AR125758A1 (es) 2023-08-09

Similar Documents

Publication Publication Date Title
MX2023005081A (es) Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos.
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
UY37829A (es) Muteínas de interleucina 21 y métodos de tratamiento
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
MX2023013382A (es) Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
TW202617780A (zh) 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
BR112018077362A2 (pt) conjugados para edição de superfície de célula-alvo
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
WO2020172596A8 (en) Anti-tcr antibody molecules and uses thereof
UY38049A (es) Anti-pd-1 anticuerpos y métodos de tratamiento
MX2018012460A (es) Composiciones de conjugados de acido nucleico dirigido.
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1120976T1 (el) Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
BR112015014751A2 (pt) anticorpos anti-tau humanos
MX2019012280A (es) Composiciones dirigidas.
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
MX2024005009A (es) Dominios de union anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
PE20190229A1 (es) Anticuerpos anti-fcrn
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
PE20141173A1 (es) Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas